ACDM News Item

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Date: August 4, 2026

Thank you to the Regulatory Considerations DMEG for sharing this update.

Health Canada published a Draft guidance on decentralized clinical trials. This is part of Health Canada’s effort to modernize clinical trial regulation to allow for new trial types and designs. The guidance applies to phase I-IV trials involving pharmaceuticals, biologics and radiopharmaceuticals intended for human use. It does not apply to medical devices, natural health projects or foods for special dietary purposes.

The ACDM Regulatory Considerations DMEG will be reviewing the draft guidance and publishing a summary of the points that impact data managers. In the interim you can read the draft guidance here: Health Canada Draft guidance on decentralized clinical trials or download here.

Meet the DMEG here

Explore More News

Welcome Mednet as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Mednet as a new . . .

Welcome Allucent as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Allucent as a . . .

Welcome KCR as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome KCR as a new . . .

Welcome Debiopharm as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Debiopharm as a . . .

HMA/EMA joint Big Data Steering Group: Big Data Workplan 2023-2025

The joint HMA-EMA Big Data Steering Group (BDSG) have released their latest workplan, . . .

ACT EU PA04 – Multi-stakeholder Workshop on ICH E6 R3

As part of the Accelerating Clinical Trials in the EU (ACT EU) multi-annual workplan . . .

European Medicine’s Agency – Reflection paper on the use of artificial intelligence in the lifecycle of medicines

The EMA has opened a public consultation on a reflection paper presenting views . . .

Welcome Instem as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Instem as a new . . .

Regulatory Considerations Expert Group reviews draft FDA Guidance

The ACDM Regulatory Considerations Expert Group have reviewed and submitted comments on . . .

ICH GCP E6 Revision 3 is here. Regulatory Considerations Expert Group to review

The R&D industry, especially those that are working on clinical trials, have been . . .

Welcome Algorics as a new corporate member

The ACDM: Association for Clinical Data Management is delighted to welcome Algorics as a . . .

Consultation response on legislative proposals for clinical trials

The MHRA have published the public consultation response to the proposals to reform the . . .